[Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state].
Kiso
Y
Y
Kyoto Pharmaceutical University, Japan.
D000595:Amino Acid Sequence; D019380:Anti-HIV Agents / Q000737:chemistry / Q000627:therapeutic use; D015195:Drug Design; D006678:HIV / Q000201:enzymology / Q000235:genetics; D016333:HIV Protease / Q000737:chemistry / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D008968:Molecular Conformation; D008969:Molecular Sequence Data; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019469:Indinavir; D016333:HIV Protease; D019258:Saquinavir; D019438:Ritonavir